AC Immune SA (ACIU) Tops Q3 EPS by 3c Nov 4, 2025 08:07AM
AC Immune publishes TDP-43 PET tracer data in Nature Communications Oct 24, 2025 08:50AM
AC Immune SA (ACIU) PT Lowered to $12 at H.C. Wainwright May 1, 2025 07:25AM
AC Immune SA (ACIU) Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Apr 2, 2025 06:26AM
AC Immune SA (ACIU) Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome Dec 10, 2024 07:01AM


Nov 14, 2024 07:00AM AC Immune SA (ACIU) Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056
Sep 18, 2024 06:41AM H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU)
Sep 17, 2024 07:00AM AC Immune SA (ACIU) Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
Aug 28, 2024 09:01AM AC Immune's (ACIU) PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
Jul 31, 2024 08:32AM AC Immune SA (ACIU) Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
Jul 25, 2024 07:00AM AC Immune's (ACIU) ACI-35.030 Granted FDA Fast Track Designation for Alzheimer’s Disease